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Abstract
Introduction The rapid expansion of the Internet and
computing power in recent years has opened up the pos-
sibility of using social media for pharmacovigilance. While
this general concept has been proposed by many, central
questions remain as to whether social media can provide
earlier warnings for rare and serious events than traditional
signal detection from spontaneous report data.
Objective Our objective was to examine whether specific
product–adverse event pairs were reported via social media
before being reported to the US FDA Adverse Event
Reporting System (FAERS).
Methods A retrospective analysis of public Facebook and
Twitter data was conducted for 10 recent FDA postmar-
keting safety signals at the drug–event pair level with six
negative controls. Social media data corresponding to
two years prior to signal detection of each product–event
pair were compiled. Automated classifiers were used to
identify each ‘post with resemblance to an adverse event’
(Proto-AE), among English language posts. A custom
dictionary was used to translate Internet vernacular into
Medical Dictionary for Regulatory Activities (MedDRA)
Preferred Terms. Drug safety physicians conducted a
manual review to determine causality using World Health
Organization-Uppsala Monitoring Centre (WHO-UMC)
assessment criteria. Cases were also compared with those
reported in FAERS.
Findings A total of 935,246 posts were harvested from
Facebook and Twitter, from March 2009 through October
2014. The automated classifier identified 98,252 Proto-
AEs. Of these, 13 posts were selected for causality
assessment of product–event pairs. Clinical assessment
revealed that posts had sufficient information to warrant
further investigation for two possible product–event asso-
ciations: dronedarone–vasculitis and Banana Boat Sun-
screen–skin burns. No product–event associations were
found among the negative controls. In one of the positive
cases, the first report occurred in social media prior to
signal detection from FAERS, whereas the other case
occurred first in FAERS.
Conclusions An efficient semi-automated approach to
social media monitoring may provide earlier insights into
certain adverse events. More work is needed to elaborate
additional uses for social media data in pharmacovigilance
and to determine how they can be applied by regulatory
agencies.
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Key Points
Previous work has established that social media can
be a viable source for pharmacovigilance signals by
drawing information directly from patients that may
not have been otherwise reported to regulatory
agencies or industry.
Of 10 recent postmarketing safety signals from the
US FDA, public Facebook and Twitter posts showed
mentions of one product–event pair before cases
were reported to the traditional spontaneous report
system.
Social media can be an adjunct to traditional safety
reporting systems to possibly uncover postmarketing
safety signals more rapidly, although considerations
of noise and volume need to be further characterized.
1 Introduction
Clinical trials are imperative for evaluating the safety and
efficacy of new medical products; however, because of
patient selection criteria, small sample sizes, and short
durations, they provide limited information on rare harms.
As a result, traditional clinical drug trials are not designed
to detect rare adverse drug events. This is exemplified by
the fact that over one-half of approved drugs have serious
adverse events (AEs) identified that are not detected before
approval [1]. In addition, existing postmarket AE reporting
systems are significantly underutilized by clinicians and
patients. It has been estimated that as much as 96% of
adverse drug events go unreported to regulators [2].
The normative and burgeoning online representation of
human knowledge and the corresponding growth of com-
puting power to analyze unstructured information offer
novel opportunities to access the variety of patient-gener-
ated experience, which has been referred to as ‘‘digital
disease detection’’ when applied to health [3]. Adoption of
social media tools and smartphones has surged. The USA
alone has 160 million Facebook users [4] and 140 million
Twitter users [5]. In the health domain specifically, 59% of
US adults had looked online for health information in the
past year, and 35% had gone online specifically to deter-
mine a medical condition [6]. A high volume of discussions
about medical products is occurring online, with patients
using social media to publicly share concerns and reactions
to medications. There is increasing interest in exploring the
use of social media data for pharmacovigilance, but ques-
tions remain regarding how to validate and best leverage
this data source.
The general benefits and limitations of using social
media for pharmacovigilance have been reviewed exten-
sively [7–15]. One area of research has focused on creating
online electronic tools that may expedite case reporting by
incorporating user-friendly formats, generally referred to as
‘crowdsourcing’ [16]. Data mining or ‘social listening’
case studies have established a base of applied examples of
how generally unstructured online electronic sources can
be used to derive drug safety information from news and
social media, commonly including Twitter, Facebook,
Google?, patient forums, news reports, blogs, and others.
Notable among these are studies evaluating online discus-
sions of benfluorex [17], antibiotics [18], human papilloma
virus (HPV) vaccine and infertility [19], oral antineoplastic
drugs [20], duloxetine [21], anti-Parkinsonian agents [22],
and opioid analgesics [23]; a study by Coloma et al. [19]
used assertion analysis to demonstrate a positive associa-
tion between rosiglitazone and cardiovascular events in
posts acquired from Twitter. Data mining of web search
logs has also been considered for pharmacovigilance and
drug safety surveillance [24, 25].
Data mining approaches to social media for pharma-
covigilance have been published by other academic groups
and evaluated in the conduct of the research presented here
[26–37]. However, an outstanding fundamental question is
whether analysis of social media could lead to earlier
detection of rare and serious AEs. This is the objective of
traditional spontaneous reporting and represents a high-
value use case by which to evaluate social media, espe-
cially for regulatory purposes.
It was hypothesized that warnings of safety signals for US
FDA-regulated medications would have been generated ear-
lier by monitoring social media in the period prior to the
discovery of the safety signals via the current pharmacovig-
ilance surveillance system, the FDA Adverse Event Reporting
System (FAERS). The objective of this study was to examine
whether cases of specific product–event pairs were reported in
social media before they were reported to FAERS.
2 Methods
2.1 Study Overview
The main study outcome was to determine whether social
media posts for selected product–event pairs occurred prior to
the date of the first FAERS case report and the date when the
FDA first considered the reports in FAERS a potential safety
signal. The date of the potential safety signal was the time at
which the FDA first determined through routine pharma-
covigilance that evidence of a concern was sufficient and that
a formal safety review would be required. Retrospective
social media data were acquired and processed to remove
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spam and duplicates and to identify AEs. Causality assess-
ment was conducted by an independent third party.
The study process was as follows:
1. Product–event pairs were identified for retrospective
analysis.
2. Search terms were selected to identify products,
including brand and generic names, and common
misspellings.
3. Medical Dictionary for Regulatory Activities
(MedDRA) Preferred Terms (PTs) indicative of
the symptomology of the MedWatch alerts were
identified.
4. Queries were submitted to a third-party vendor to
gather historical data.
5. A vernacular-to-regulatory dictionary was applied to
convert the verbatim post text to MedDRA PTs.
6. Machine learning algorithms were run on the data to
automatically identify ‘posts with resemblance to
adverse events’ (Proto-AEs), delete spam posts,
consolidate duplicates, and remove personally iden-
tifiable information.
7. Symptomatic descriptors for each product–event
association were used to identify posts for manual
review.
8. An experienced drug safety physician manually
curated auto-tagged Proto-AEs.
9. An independent third-party medical reviewer con-
ducted causality assessments on the resulting posts.
10. Social media data were reviewed for concordance
with the dates provided by the FDA regarding when
the safety signals were first identified using the
agency’s standard signal detection processes.
2.2 Data Sources and Study Period
The data source was English language public social media
posts from Facebook and Twitter collected between March
2009 and October 2014 regardless of geographic location.
Follow-up duration was the same for all product–event
pairs, starting two calendar years before the first day of the
month in which the FDA safety signal was first identified.
Social media data from public Facebook and Twitter
posts were obtained from an authorized third-party data
vendor, since an estimated 90% of all Twitter accounts [5]
and 25% of all Facebook accounts [4] are publicly acces-
sible. The commercially available service provided the
verbatim text of the body of the original post along with
metadata such as timestamp, a link to the original content,
and, if available, the poster’s gender and geographical
information. Posts that were truncated but still described
AEs and contained links to original content (e.g., a Tweet
that linked to a longer post on the discussion board
MedsChats.com) were followed to retrieve the full text.
The FDA provided the month and year that the selected
safety signals were first identified through the use of rou-
tine monitoring of FAERS in combination with other
routine data sources for pharmacovigilance. Public data
from FAERS were used to extract information on indi-
vidual cases received by the FDA. Public FAERS data do
not contain case narratives, so further information could
not be used to determine exact date of onset or a detailed
causality assessment. See the Electronic Supplementary
Material (ESM) 1 for a list of data elements that were
available in the public FAERS dataset and used in this
analysis.
2.3 Drug–Event Selection
A total of 15 safety signals, identified between January
2011 and October 2014, retrieved from the FDA website
were initially considered for use in the study [38]. The time
period was selected based on the availability of historical
social media data from a third-party data vendor (Datasift).
The final list selected for analysis resulted in 10 product–
event pairs (Table 1). The final 10 products were nine
Table 1 Product–event pairs selected for analysis
Drug Adverse event Month identified
1 Lisdexamfetamine Raynaud’s phenomenon Mar 2011
2 Olmesartan Sprue-like enteropathy Sep 2011
3 Methylphenidate Priapism Sep 2011
4 Topical econazole Increased international normalized ratio (INR) Feb 2012
5 Pradaxa Angioedema Apr 2012
6 Dronedarone Vasculitis Apr 2012
7 Hydroxyzine Serious injection site reactions Jul 2012
8 Ziprasidone Drug reaction with eosinophilia and systemic symptoms (DRESS) Jun 2014
9 Tecfidera Progressive multifocal leukoencephalopathy (PML) Oct 2014
10 Banana Boat Sunscreen Spray Flammablility resulting in serious skin burns Jun 2012
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prescription medications and one over-the-counter con-
sumer product. See the ESM 2 for a complete list of pro-
duct–event pairs considered for analysis.
The following rules reduced the list of 15 initial safety
signals to 10:
• Of the 15 safety signals, three were attributed to
dronedarone, with another two attributed to Tecfidera.
Three of these earlier reported product–event pairs with
identical products were removed after it was deter-
mined that including multiple events would complicate
the selection of negative controls by restricting the
number of feasible negative controls. The process for
selecting negative controls is described in Sect. 2.5.
• Acetaminophen–skin reactions was eliminated because
the amount of curation required to review the high
volume of posts for ‘acetaminophen’ and ‘paracetamol’
was too onerous to be feasible in this study.
Of note, the safety signal for hydroxyzine was specific
to an injectable formulation, but all mentions of hydrox-
yzine were analyzed to reduce the possibility of missing
reports by using injectable-specific search terms.
2.4 Selection of Search Terms
The brand names and misspellings in Table 2 were iden-
tified for each of the products of interest from a list of
hypothesized spelling variants, using the public Twitter
search. This is because drugs posted in social media can
take on a variety of forms; aside from being referred to by
various brand names and active ingredients, medical
products can be misspelled or referred to in more general
terms (synecdoche). Any search term that resulted in more
than 10 posts was included. To maximize signal-to-noise
ratio, an additional search criterion was added to include
any posts mentioning ‘vivance’ (a common misspelling of
Vyvanse) but to exclude ‘la vivance’, a common French
word, because the concept is semantically unrelated to drug
safety.
For the purpose of identifying cases in FAERS, which
contains curated data with corrected misspellings, products
were searched for using properly spelled brand and generic
names.
2.5 Selection of Controls
The selection of negative controls was modeled after the
approach taken by Harpaz et al. [39] while establishing a
time-indexed reference standard for adverse drug reactions.
This approach defines negative controls by randomly
pairing each product that appeared in the set of positive
controls with one event that appeared in the set of positive
controls. This process is repeated until each product is
paired with at least one negative control event.
In addition, we avoided assigning negative controls
where the signs and symptoms indicative of the negative
control medical concept may be associated with a product’s
indication and therefore may trigger a false positive.
FDA safety reviewers then checked product labeling to
ensure that the events were not AEs listed in the product
labeling for the randomly assigned negative control prod-
uct. The most recent product label in October 2014 that
was available from the National Library of Medicine
DailyMed site was used [40]. Of the resulting matches,
four were excluded because the AE was listed as an AE in
the label for that drug. The six resulting product–event
pairs were selected as negative controls: dabigatran etexi-
late (Pradaxa) and Raynaud’s phenomenon, dimethyl
fumarate (Tecfidera) and priapism, hydroxyzine (Atarax)
and increased international normalized ratio (INR),
ziprasidone (Geodon) and vasculitis, lisdexamfetamine
(Vyvanse) and drug reaction with eosinophilia and sys-
temic symptoms (DRESS), olmesartan (Benicar) and pro-
gressive multifocal leukoencephalopathy (PML).
Table 2 Search strings for
selected products
Product Search terms
1 Lisdexamfetamine Lisdexamfetamine, lisdexamphetamine, vyvanse, vyvance, vivance,
vayvanse
2 Olmesartan Olmesartan, benicar
3 Methylphenidate Methylphenidate, methylphenadate, ritalin, ritilin, concerta, daytrana,
quillivant
4 Topical econazole Econazole, spectazole
5 Pradaxa Pradaxa, predaxa, dabigatran
6 Dronedarone Dronedarone, multaq
7 Hydroxyzine Hydroxyzine, hydroxizine, vistaril, atarax
8 Tecfidera Dimethyl fumarate, tecfidera, tecfedera
9 Ziprasidone Ziprasidone, geodon
10 Banana Boat Sunscreen
Spray
Banana boat sunscreen, banana boat sunblock, banana boat spray, banana
boat aerosol
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2.6 Definitions
We utilized a previously created colloquial symptom
dictionary in the social media listening platform to map
colloquial phrases in social media posts to MedDRA, the
international medical terminology developed under the
auspices of the International Council for Harmonisation
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use (ICH) [41]. The MedDRA
taxonomy comprises a five-level hierarchy of terms and
codes describing, to varying degrees of specificity, a wide
range of medical conditions, diagnoses, treatments,
investigations, and signs and symptoms. The hierarchical
levels are defined by degree of specificity, starting at the
most general ‘System Organ Class’ (SOC) that describes
organ- or site-specific disorders. The fourth level of
specificity, ‘Preferred Term’ (PT) was chosen for this
analysis. A PT represents a distinct clinical concept and is
routinely used in pharmacovigilance, including in FAERS
data. As described elsewhere [29], the colloquial symp-
tom dictionary was developed over four years through a
manual curation process. When curators encountered
vernacular terms in social media describing medical
conditions, the phrases were added to the dictionary. The
dictionary encompasses euphemisms (e.g., ‘‘I look like a
lobster’’ codes to Erythema), combined words in the form
of hashtags (denoted in social media using the # symbol),
variations between American and British English, mis-
spellings, abbreviations, homonym confusion, affixes
(e.g., plural -s, past tense -ed), homographs, heteronyms,
metonyms or synecdoche, and other facets of semantics.
At the start of this study, the colloquial symptom dic-
tionary contained 8857 vernacular terms mapped to 1956
of the most common PTs. Phrases are mapped to the
MedDRA (version 18) PT level since PTs represent
distinct clinical concepts and are routinely used in phar-
macovigilance, including coding AEs in FAERS data.
Each colloquial phrase identified in social media
describing a symptom was mapped to a MedDRA PT as
described elsewhere [29, 42]. For our study, all PTs
identified in this analysis for the 10 AEs of interest were
available in the colloquial symptom dictionary, including
all corresponding AE synonyms.
Another research group found low recall when using a
lexicon-based approach [26]. The lexicon studied was
optimized for searching biomedical literature. As such,
we would not expect that specific lexicon to perform
well in social media posts in Twitter and Facebook.
However, the lexicon used in our analysis was specifi-
cally generated based on empirical observation of patient
conversations in social media. Therefore, the results
observed by Nikfarjam et al. [26] cannot be generalized
to this study.
2.7 Case Detection
The unit of analysis was a single post in Facebook or
Twitter that mentioned both a product name and an AE.
Those AEs mentioned with a specific product are referred
to as Proto-AEs, a term used to differentiate AEs described
in social media posts from AE reports that have been vetted
to meet the minimum regulatory requirement for reporting
AEs, such as those in FAERS. Proto-AEs are conceptually
modeled on the regulatory reporting definition, as we
consider a network username to be similar to a patient
identifier for a MedWatch report.
We identified standardized symptom lists and definitions
that were used to consistently evaluate the Proto-AEs
identified in social media posts. This was because patients
were more likely to report signs and symptoms of an AE
than a medical diagnosis.
To screen social media posts for cases for causality
assessment, symptoms related to the 10 AEs of interest
needed to be identified (see ESM 3) to build an event
profile for automated Proto-AE detection.
The process used was as follows:
• If available, Standardized MedDRA Queries (SMQs)
were identified, yielding definitions for two AEs:
angioedema and vasculitis.
• All terms related to medical devices, injection, infu-
sion, implant, stents, vaccinations, and syringes or
needles were removed from the angioedema list
because only solid oral formulations were under review
among drug products.
• Injection site-related PTs were selected from the
Extravasation events MedDRA SMQ.
• To give preference to regulatory precedent on defini-
tions, the FDA website was searched (using search
engine-indexed site-specific syntax) to identify addi-
tional definitions, resulting in the identification of
symptom lists for renal impairment and sprue-like
enteropathy.
• If other definitions were still not available, clinical
reference books (e.g., Merck Manual) and trusted
medical websites (e.g., Mayo Clinic and National
Institutes of Health [NIH]) were consulted and con-
verted into MedDRA PTs.
The number of unique PTs for each condition varied
considerably; angioedema had by far the highest number of
symptoms.
2.8 Indicator Score Calculation
A machine learning algorithm was employed to distinguish
posts containing relevant drug safety information from
non-informative posts. This was achieved using a statistical
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approach for automated document classification that cate-
gorized each post as either a Proto-AE or a non-Proto-AE,
based on a manually coded training set using Certified
MedDRA Coders, as previously described [29, 42]. This
training set consisted of data collected from Facebook and
Twitter between October 2012 and December 2014 using
application programming interfaces made publicly avail-
able by Facebook and Twitter. There was no overlap
between the training set data and the study data. This
involved feature extraction, a process by which each post
was broken up into a set of discrete elements that were then
tallied to determine the number of times each element (or
feature) occurred in posts that had been manually coded as
Proto-AEs and in posts that had been coded as non-Proto-
AEs. To improve computational efficiency, the text was
parsed using a single tree structure, based on the dic-
tionary-matching algorithm originally developed for
HealthMap, adapted to identify mentions of products and
symptoms [29, 42]. Loading the product and symptom
taxonomies into a single tree structure enabled the post to
be processed a single time to identify tokens that may have
represented both products and symptoms. Next, all punc-
tuation was removed, and the post was divided into tokens
comprising one- to three-word phrases. Finally, each token
was processed and matched against the vernacular dic-
tionary. Positive matches were established when a ‘leaf’
was reached in the tree and a phrase for either a product or
a symptom was identified based on the taxonomy.
After the feature extraction algorithm was run on the
input, the classifier, developed through statistical machine
learning computation, was applied to each post. The model
for the classifier was taken from Robinson’s approach to
eliminating spam in email [43]. Using a Bayesian proba-
bilistic model and drawing on a training dataset containing
more than 360,000 manually classified posts, the software
assigned each post an indicator score on a scale of 0 to 1.
For each feature extracted from a post, we calculated a
probability score representing the likelihood that the post
was a Proto-AE based on the manually classified corpus.
We then combined probabilities across features using the
inverse chi-squared function and calculated an overall
indicator score, as detailed below. A score close to 0 meant
there was a low probability that the post was related to an
AE discussion (usually spam), whereas a score close to 1
indicated a high probability that the post was related to an
AE discussion. In general terms, each new token was
compared with the priors, and two probabilities were cal-
culated based on the number of times the token appeared in
positive and negative posts in the manually classified pri-
ors. Finally, we empirically determined that if a post con-
tained no identifiable symptom, it was less likely to contain
a true AE report. To account for this, and as a performance
improvement measure, we therefore deducted a penalty of
0.2 from the indicator score if the post did not contain any
identifiable symptoms.
The process for computing the probabilities, combining
them, and producing an indicator score was as follows. For
each token ‘w’:
• b(w) = (number of positives containing w)/(total num-
ber of positives)




p(w) is the ‘raw’ probability that the document is a
positive (AE) given that it contains word ‘w’.
To adjust for rare tokens, i.e., phrases that did not occur
frequently or at all in the training set, the following sta-
tistical adjustment was undertaken:
f ðwÞ ¼ ðs  xÞ þ ðn  pðwÞÞ
sþ n
f(w) is a scaled or ‘weighted’ transformation of p(w).
The weighting is based on priors as well as the frequency
of w in the training set.
s: ‘strength’ assigned to background (training)
information
x: assumed probability of spam for unknown token
n: number of examples containing w
Strength (s) and probability of positive (x) are priors. 1.0
and 0.5 are considered neutral values for s and x, respec-
tively; in our implementation, we used 1.4 for the value of
s and 0.6 for the value of x. These values were determined
by experimentation, namely, checking performance metrics
for a range of values and selecting the values yielding the
best performance. No formal optimization methodology
was applied for this process.
Probabilities were derived using Fisher’s method of
combining probabilities, where C-1 is shorthand for the
inverse chi-squared function:





Complementary probabilities were combined in this
manner:
S ¼ C1 2 ln
Y
w
1 f ðwÞ; 2n
 !
The indicator score was then calculated by averaging the
combined probabilities with the inverse probabilities.
I ¼ 1þ H  S
2
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We average the positive score (H) and the negative
score (S) to produce a bimodal distribution of indicator
(I) values. That is, with the resulting distribution of I in our
dataset, we see large numbers of posts scoring either very
low (high likelihood of spam) or very high (high likelihood
of AE) and a smaller number scattered across the middle.
The middle of the distribution represents content that the
algorithm determined to be ambiguous. Since there is not
enough human analyst time to check and reclassify all
posts, we can then focus our analyst efforts on posts falling
in the middle of the distribution. Second, the nature of the
distribution makes the performance less sensitive to the
exact indicator threshold value, since we place the
threshold near the middle of the distribution.
Posts with indicator scores of 0 were generally spam,
e.g., advertisements, coupons, or other posts containing
text clearly generated by bots. Posts with indicator scores
[0 were called ‘mentions.’
An analysis of classifier performance suggested that
optimal thresholds for removing irrelevant posts without
excessively sacrificing true positives were indicator
scores of 0.6 to 0.7 [42]. In the previous analysis, posts
with indicator scores of C0.65 had a positive predictive
value of approximately 0.5 (i.e., 5 of every 10 posts
would be relevant for drug safety), while keeping 92% of
true AE posts.
2.9 Human Curation
Given the nuanced nature of social media language, pre-
vious experience has consistently suggested that review by
a human curator is necessary on some posts that have been
automatically identified as AEs by the classifier. This
process helps to remove false positives, continuously
improve the classifier, and expand the symptom and pro-
duct taxonomies. This approach, called ‘active learning,’
introduces a feedback loop between the human curators
and the automated classifier [29]. The high volume of data
in this study meant it was not practical to manually review
every auto-tagged post; therefore, we established a
threshold to identify potentially ambiguous posts that may
require curation based on previous analysis of social media
data using the machine classifier [42]. Posts with indicator
scores of at least 0.65 were reviewed by a team of human
curators that included Certified MedDRA Coders and
medical professionals with a focus on removing false
positives, called ‘primary curation.’ All curators received
standardized training on curation methods for social media
data, according to the MedDRA coding standards and
ICH-endorsed guidelines. Standard MedDRA practices
were used, including objective coding without any attempt
to interpret or infer beyond the stated text. Curators receive
annual refreshers, as well as training on each new release
of MedDRA. Primary curation is an ongoing process that
is conducted for drugs in the general system; however, to
prepare the data for causality assessment in this analysis,
an additional round of curation was needed.
Accordingly, ‘secondary curation’ was then conducted
to identify relevant posts of interest for the hypothesis in
this paper. An experienced drug safety physician (HVL)
reviewed posts that had undergone primary curation for a
given drug that had any symptom (e.g., from the SMQ list)
associated with the product–event pair from positive
associations and negative controls. Posts that appeared to
describe the product–event pairs of interest were extracted
for causality assessment. For SMQs, the presence of any
symptom was not sufficient to trigger a positive match; the
symptoms listed for SMQs in ESM 3 are often non-spe-
cific. As such, it was left to the discretion of the physician
reviewer to determine whether the constellation of symp-
toms described was sufficient for a plausible positive
match.
2.10 Causality Review
World Health Organization-Uppsala Monitoring Centre
(WHO-UMC) criteria for causality assessment [44] were
assigned to each post identified during secondary cura-
tion. To accomplish this, the text of the post, along with
date and data source, was sent to WHO-UMC for inde-
pendent review by an experienced senior medical offi-
cer (IRE). Posts were classified as being ‘certain,’
‘likely,’ ‘possible,’ ‘unlikely,’ or ‘unclassified.’ The
differentiating factor between certain/likely and possible
was the presence of time-to-event information; more
granular and plausible time information elevated a case
to certain as opposed to likely. It was assumed that most
social media posts would likely fall in the possible cat-
egory since time-to-event information is not routinely
reported by patients.
2.11 Ethics Statement
All social media data used in this analysis came from
public sources. Prior to causality assessment, posts were
stripped of personally identifiable information (PII), such
as screen names, user names, first and last names, and
addresses. A hybrid automated–manual process was used
to remove first and last names. Using a ‘PII dictionary’
containing a few hundred thousand names from a global
database of values [42], the software removed from the
posts any names that were contained in the dictionary. In
addition, text-based pattern matching was used to remove
structured information (e.g., phone numbers, email
addresses) that could lead to individual identification, other
than for the needs of manual review. ‘Verbatim’ post text
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presented in this manuscript has been paraphrased and/or
altered in non-meaningful ways to protect patient identity
and prevent unmasking using Internet search engines. AE
data from FAERS were also publicly available in an
anonymized format. Since all primary data sources used in
the analysis were publicly available, no institutional review
board approval was sought.
3 Results
3.1 Data Processing Results
Figure 1 represents the schematic flow of posts and steps
taken in data cleaning as well as the number and percent of
posts resulting from each process. We started with an
Fig. 1 Data processing results. Public social media data were
obtained for Facebook and Twitter, with 935,246 posts identified
where each of the 10 products under review were mentioned. An
automated classifier was used to remove spam, followed by exclusion
of verbatim duplicate posts. Posts with an indicator score of C0.65
were considered a ‘post with resemblance to an adverse event’ and
manually curated to remove false positives. The resulting 13 posts
that mentioned product–event associations from alerts or negative
controls were assessed for causality by an independent third party. Six
posts contained certain, probable, and possible cases. AE adverse
event, Proto-AE post with resemblance to an adverse event
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initial dataset of 935,246 posts containing text of selected
products. These were posted on public Facebook and
Twitter accounts from March 2009 to October 2014. Spam
posts were identified and eliminated based on indicator
scores (less than zero) implying that the posts did not
contain text that met our requirements (i.e., posts with the
name of a product and only an emoticon, or in non-English
languages). This spam-elimination step resulted in the
removal of about 25% (n = 230,963) of the remaining
posts, leaving a corpus of 704,283 non-spam posts men-
tioning the products of interest. Next, verbatim duplicates
(8.3%, n = 58,188) were consolidated. A total of 98,252
Proto-AEs were then identified based on indicator scores of
C0.65, representing about 15% of the remaining posts.
After primary and secondary manual curation, which
occurred over the course of three months, 13 posts were
identified as possibly relevant and were then submitted for
causality assessment. This process resulted in six posts of
interest that described certain, probable, and possible cases.
3.2 Comparison of Twitter and Facebook Data
Volume of mentions varied considerably by product, with
controlled substances (e.g., lisdexamfetamine, methylphe-
nidate) showing much higher volume due in considerable
part to Internet pharmacy advertisements (Fig. 2). Mentions
for the products of interest varied over time, with rapid
increases after newproduct launches (e.g., lisdexamfetamine
and Tecfidera). Surges in post counts generally tended to
express excitement about the new products among patient
communities, but also included sales and stock price fore-
casts for finance audiences. Most posts came from Twitter,
compared with Facebook (Fig. 3). Twitter generally yielded
a higher volume of mentions overall due to the prevalence of
pharmacy advertisements, references to financial reporting,
and links to medication-related news articles or literature.
The percent of posts from Facebook varied from 1.4% (lis-
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Fig. 2 Volume of mentions of selected products in public Twitter and Facebook social media data. Mentions for the products of interest varied
























Fig. 3 Comparison of public Twitter and Facebook data for purposes
of medical product safety surveillance. Social media data from public
Facebook and Twitter posts were analyzed. A greater volume of posts
originated from Twitter than from Facebook
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[Tecfidera]). The higher proportion of posts from Facebook
for dimethyl fumarate originated from patients posting
within open patient groups rather than individuals posting on
their personal pages.While Twitter typically generates more
posts mentioning medical products, Facebook data typically
consists of higher-quality posts with more detailed infor-
mation. Facebook’s post format and its numerous open
patient groups provide a platform for patients to share their
experiences without the character limits imposed by Twitter.
3.3 Results of Causality Assessment
In total, 13 posts were submitted to WHO-UMC for
causality assessment. The assessor was provided with the
complete post of the text and told which product–event pair
was under examination for each. The posts covered 5 of the
10 product–event pairs identified in Table 1: ziprasidone–
DRESS, methylphenidate–priapism, dimethyl fumarate–
PML, dronedarone–vasculitis, and Banana Boat Sunscreen
Spray–skin burns. The manual curator assigned the fol-
lowing scores to each of the 13 product–event pair posts:
ziprasidone–DRESS: three unlikely posts; dronedarone–
vasculitis: three possible posts, one probable post;
methylphenidate–priapism: three unlikely posts; dimethyl
fumarate–PML: one unlikely post; Banana Boat Sunscreen
Spray–skin burns: two certain posts. Of the posts given the
classification of unlikely, the greatest limitation was that
the vernacular language used was not specific enough to
constitute a causal relationship with the paired condition.
For example, one Twitter post stated, ‘‘I’m severely aller-
gic to geodon—had to go to the hospital just 8 hours after I
took my dose.’’ The phrase ‘‘severely allergic’’ did not
adequately describe DRESS. Similarly, another post read,
‘‘my doc wants me to try a new anti-psychotic. im fuckin
terrified, i dont wanna, i almost lost my life a few times
from it, im the only person i know who’s allergic to abilify
and geodon.’’ In this instance ‘‘almost lost my life’’ did not
specifically suggest DRESS. In a third example, ‘‘So, they
took me off Geodon because I had an extreme attack last
week and was trying to go into cardiac arrest, that was fun
[truncated].’’, again ‘‘extreme attack’’ and ‘‘trying to go
into cardiac arrest’’ did not provide enough detail to
determine a causal relationship to DRESS. All three of
these posts would be considered serious AEs and poten-
tially useful information, but they did not meet the strict
intent of this analysis. These posts were all reported in
social media before the FDA signal threshold for ziprasi-
done–DRESS had been reached from spontaneous reports.
For dimethyl fumarate–PML, a single Facebook post
was identified from secondary curation that was eventually
adjudicated by WHO-UMC to be unlikely: ‘‘I tried taking
Tecfidera and it made me SO sick I thought I was gonna
die. Now I’m thinking of switching to Tysabri, but I tested
positive for JC virus. My index value was 1.5 and the
doctor told me that risk for PML was low at that range. Just
wondering if anyone else is JCV positive and doing well on
Tysabri?’’ In this instance, the link to PML could not be
definitively established because no specific adverse drug
reaction was being described. However, it is also worth
noting that JC virus seropositivity is considered the dif-
ferentiating risk factor for PML with this medication [45].
In strictly medical terms, the combination of a positive JC
virus test and ‘‘SO sick I thought I was gonna die’’ may not
be sufficient to describe PML, but nonetheless implies a
potentially severe and particularly inauspicious event
experienced by the patient. This post was reported in
Facebook before the FDA signal threshold for dimethyl
fumarate–PML had been reached.
For dronedarone, four specific posts mentioned symp-
toms that were consistent with vasculitis, all observed in
Twitter, but two of these originated in a patient discussion
board. One example stated, ‘‘Been on 400 mg of Multaq,
29 daily, for almost 6 weeks. Four days ago, noticed I had
a rash on the palms of both my hands with dots that kind of
look like small blood blisters.’’ This case was considered
probable by the WHO-UMC causality reviewer because of
the realistic time-to-onset mentioned in the post. The
symptomology in the specific location of the extremities is
a known characteristic of vasculitis, with the description of
‘‘like small blood blisters’’ further confirming the
suspicion.
Finally, hypersexuality has long been associated with
synthetic pharmaceutical stimulants, from amphetamine to
methylphenidate and others [46, 47]. Identifying priapism
cases specifically within a background of normative
hypersexual references led to difficulty in drawing a causal
link. For example, ‘‘@user says …’’is one of the side
effects of ritalin a hard cock?’’ LMFAO.’’ Since no
pathology is described in this post, the WHO-UMC
reviewer made the determination that it had unlikely causal
connection. The other two posts reviewed for this product–
event pair also had similar limitations.
3.4 Review of Social Media Posts
The 13 posts identified as a result of secondary curation
appeared to be discussing symptoms associated with the
pre-specified product–event pairs. No posts were found to
contain symptoms for the negative controls after curation.
The 13 posts were associated with 2 of the 10 FDA-iden-
tified safety signals, specifically dronedarone-associated
vasculitis and skin burns resulting from Banana Boat
Sunscreen Spray (Table 3). There did not appear to be
specific symptomology discussed in social media for the
other eight safety signals identified by routine surveillance
methods.
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For Banana Boat Sunscreen Spray, the first mention was
on Facebook on 1 June 2012, followed a few hours into the
next day on Twitter. Over the next week, 19 Facebook
posts and 144 Twitter posts discussed this topic, fueled
initially by a local television morning news story on 3 June.
3.5 Timing of Social Media Posts Compared
with FAERS Reporting
For dronedarone–vasculitis, the social media case was
identified from Twitter on 5 December 2010. No cases
were identified in Facebook. The first FAERS primary
suspect drug case was received on 7 July 2010, with signal
detection reported by the FDA on 15 April 2012. Four
social media reports were evaluated as possible (n = 3),
probable (n = 1), or certain (n = 2), compared with 10
unique Individual Case Safety Reports (ICSRs) leading to
signal detection by the FDA.
For Banana Boat Sunscreen–skin burns, the first social
media case was identified from Twitter on 2 June 2012,
whereas the first Facebook case was identified on 1 June
2012. The first FAERS case was received on 19 June 2012,
with signal detection reported later that month by the FDA.
Two social media reports were evaluated as possible or
probable, compared with one unique ICSR leading to sig-
nal detection by the FDA. The FAERS data suggest that
(presumably separate) events occurred on 28 May 2012 and
12 June 2012. It is possible that the case reported in social
media was the one that occurred on 28 May, but this cannot
be verified. Therefore, only a single post count was
attributed.
4 Discussion
This analysis applied strict criteria for evaluating the use-
fulness of social media data in detecting serious AEs.
Despite the very specific nature of this analysis, of the 10
safety signals studied, one was mentioned in social media
data prior to meeting FDA signal detection thresholds,
Table 3 Social media post text and causality assessment






‘‘Started multaq 4 days ago, already have strange side effects:
severe abdominal pain, shortness of breath with almost no activity.
My heart beats are even more irregular than before and now I have
on and off heart racing that I didn’t have before. I will call my
Cardi tomorrow to get off the meds’’
Likely/
probable
Twitter Possible Time relationships and absence
of other possible cause not
specified
‘‘Been on 400 mg of Multaq, 29 daily, for almost 6 weeks. Four
days ago, noticed I had a rash on the palms of both my hands with
dots that kind of look like small blood blisters. Came to this site to
see if others have the same issue’’
Probable Twitter Probably Known ADR and time-to-onset
realistic
@user besides gaining weight while on multaq, I’ve had rashes on
my hands
Probable Twitter Possible Possible, but no time info
‘‘Haven’t had severe side effects from Multaq … sometimes I get
an itchy rash along the side of my torso. Eventually it goes away so
I think it might be seasonal. I’m mostly concerned with losing a
lot of hair. My hair dresser said I was shedding a lot and I notice it
when I wash and brush my hair. Could be due to hormones but
going to get checked out. Just thought I would ask if this was also
a side effect. ##Multaq contains the active ingredient Dronedarone,
it is used to treat conditions that cause irregular heartbeat. While
hair loss is not listed as a regular side effect, there are actually
many reports from women using the medication that they have
experienced it, generally starting between 1 to 6 months, after they
have started taking it. Are there any other que…’’
Probable Twitter Possible Which ADR are we talking
about?
Banana Boat Sunscreen Spray: flammability leading to serious skin burns
‘‘Banana Boat Aerosol Sunscreen is extremely flammable. A doctor
sprayed it on then caught fire while using a BBQ grill’’
Likely Facebook Certain Certain phenomenologically
WOW… A man’s body caught fire after he applied a Banana Boat
SUNSCREEN!!! [link]
Likely Twitter Certain Certain phenomenologically
Verbatim post text has been paraphrased and/or altered in non-meaningful ways to protect patient identity and prevent unmasking using Internet
search engines
ADR adverse drug reaction, WHO World Health Organization
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whereas another appeared in FAERS prior to social media.
The events selected for this analysis were very specific
diagnoses, whereas patients are more likely to discuss their
medical conditions in common terms and symptoms.
Therefore, it was necessary to cast a wide net using a large
collection of terms consisting of any symptom that could
possibly be associated with the selected medical event.
This resulted in a very large number of collected posts that
ultimately were deemed irrelevant to the product–events of
interest, such as posts that referred to other non-medical
products or individuals (e.g., musicians) that happened to
have the same name as the chosen medical products. The
combined lexical and machine learning approach used in
this analysis had a performance of 0.88 sensitivity (recall)
and 0.68 positive predictive value (precision) [29]. This
approach was selected on the basis of performance after
comparison with other machine learning techniques [48]. A
recent analysis using Twitter and one patient forum with a
training set of 6000 posts (limited to 81 drugs) returned
recall of 0.68–0.78 and precision in the range of 0.76–0.86
with a semantic approach; by comparison, in that analysis,
a lexical approach had 0.61–0.72 recall and 0.56–0.58
precision [26].
The WHO-UMC causation scale is a high standard when
applied to social media. The drug and the AE must be well
described and specific in addition to having plausible time
relationships. Possible confounders will reduce the likely
causality. When one considers the usefulness of trawling
the Internet, WHO-UMC reviewers think of signals that
describe ‘something serious happening,’ and the ‘some-
thing’ is characterized cohesively enough to suggest the
effect is shared by a few unique individuals (generally
more than three). Seriousness should therefore be a signal
in its own right so that ‘‘extreme attack’’ and ‘‘trying to go
into cardiac arrest’’ would be as important a signal as
something with a suggestive causal link to a specified
disease entity; WHO-UMC reviewers feel that they would
always be interested in such reports when identifying and
evaluating signals. Perhaps these are the most important
contributions from social media—that an early serious
concern is expressed about a drug harm before it is
medicalized.
Why social media monitoring did not yield early safety
concerns for the other eight product–event pairs bears
consideration. One possible explanation is that the events
used in this analysis were relatively severe and/or serious,
and our assumption is that patients would have sought
medical treatment for many of these outcomes. Therefore,
there is a likelihood that a patient’s provider might find the
event to be significant enough to report, whereas a patient
might consider a more severe diagnosis to be private
information, thereby increasing the chances of it being
detected through formal reporting channels and not
mentioned on social media. Similarly, many of the events
involved in this analysis may have required formal medical
diagnosis for detection or may require medical expertise to
describe it to the extent that it might trigger a signal.
A previous study by the authors investigated concor-
dance at the MedDRA SOC level between social media
reports and FAERS data [29]. General disorders (usually
less serious) were most commonly reported in social
media, with patients describing symptoms in more general
terms, e.g. ‘‘stomach problems’’ (‘‘Abdominal symptom’’),
implying that whereas some patients are keen to describe
their side effects publicly, many do not describe symptoms
using the medical terminology needed to explicitly confirm
a certain condition or diagnosis.
This research contributes to the literature by providing a
scientific approach to identifying potential posts containing
AE information using an automated process, followed by
structured manual review by drug safety physicians,
including a process for assessing causality using an inter-
national standard.
As we mentioned above, the nature of the severe events
selected for this analysis required us to rely on a large
selection of terms for common signs and symptoms that
would provide us with a large enough corpus from which to
work. This methodology might have been improved
upon—and search results could have been much nar-
rower—perhaps by developing an algorithm for each sep-
arate event of interest or product that assigned weights to
each sign and symptom according to the likelihood that it
would indicate the event of interest.
One unresolved key question is how to operationalize
social media surveillance for regulated medical products.
Given the curation burden and the large volume of social
media data, prospective monitoring of all regulated prod-
ucts may have limitations. Social media could be used to
stimulate a safety assessment that the FDA was not already
considering. Some pharmaceutical companies have pro-
gressed to monitoring a portfolio of products [42], but
government agency monitoring of the pharmacopeia will
require additional effort. Whereas other researchers have
developed more directly automated screening methods to
identify potential posts of interest (e.g., AEs), a critical
component of our study was to elucidate a process by
which machine-identified posts could be evaluated for
causation within the existing global frameworks used by
regulators and industry. This process is a bridge between
the computer science tools and existing pharmacovigilance
methods. A future can be envisioned of greater machine
dependence, but adjudication of causality is likely to
remain a fundamentally human function.
Beyond this, the results of this analysis elicit points for
discussion. First, further research is needed to develop best
practices and methods for determining what constitutes a
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‘safety signal’ in social media. It can be hypothesized that
higher signal thresholds than those used in traditional
pharmacovigilance may be appropriate for signal detection
in social media data, as these data are not specifically
intended to be used for reporting adverse drug reactions. A
line of interdisciplinary research has been initiated to
explore alternative methods for quantitative signal detec-
tion using social media data [7] in addition to an approach
using proportional reporting ratios [42]. Second, social
listening for postmarketing safety surveillance is a new
field, and best practices are still being established. There is
some uncertainty on the appropriate use of these data from
a regulatory and patient privacy point of view.
There are several technical limitations to this study
that bear mentioning. First, there is inherent variability
across data sources that can change rapidly over time.
This may include the types of people posting on a
particular website and limitations caused by website
characteristics (e.g., character limitation). In 2015,
Facebook enacted a policy to no longer make post-level
verbatim text available for data-mining purposes, citing
privacy concerns. This effectively makes the world’s
largest social network unavailable for future drug safety
surveillance, without special dispensation. Other social
networking sites may also make their user-generated
data not public, meaning it will be inaccessible using
the methods described herein. Second, Internet vernac-
ular may not accurately reflect a medical condition. To
alleviate this limitation, the vernacular-to-MedDRA
dictionary used for this study was able to pick up on
many such peculiarities of language, but some may have
been missed. Other researchers have proposed solutions
to developing an exhaustive consumer health vocabu-
lary, which will be incorporated in future analyses
[49, 50]. Third, there is the possibility that people may
post the same information in multiple social media
platforms. As a result, some duplication may exist.
However, this was not apparent to curators while man-
ually reviewing posts for this analysis. Potential for
duplication will need to be considered in the develop-
ment of quantitative signal detection methodologies,
alongside the perennial problem that stems from the
lack of an obvious denominator for rate calculation in
spontaneously reported AE data. Finally, the manual
curation steps described here were considered necessary
to provide a medical understanding of the social media
posts. A practical limitation to including the human
curation step is in the volume of reports that can be
processed. For example, acetaminophen/paracetamol
products were not included in this analysis because the
volume was too high for manual curation. Specific
investigations may need to consider approaches that rely
more on automation.
5 Conclusion
Although we do not foresee that social media monitoring
will replace current spontaneous report systems, we present
one example of how social media listening, even for rare
and serious events, can be modeled as an early warning
system for emerging drug safety concerns. In 1999, Cobert
and Silvey [51] commented ‘‘we live in electronically
exciting times’’ in reference to the then-impending explo-
sion of Internet-based options for pharmacovigilance. A
decade and a half later, we feel that their vision for the
future of drug safety is being borne out and will continue to
expand in coming years.
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